Our Pricing

Wegovy UK Cost: How to Access Affordable Semaglutide Treatment

Published on: June 03, 2026

Searching for transparent wegovy uk cost discount code options? At Cured Pharmacy, you'll pay from £79.00 per pen with code WEIGHTLOSSNEW — lower than typical market rates — with upfront pricing, UK-registered prescribers, and discreet home delivery included.

Understanding Wegovy UK Cost and Pricing Structure

Wegovy (semaglutide 2.4mg) is a once-weekly injectable treatment licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² with weight-related health conditions [1]. The medication works by mimicking GLP-1, a natural hormone that regulates appetite and food intake, helping patients achieve sustained weight reduction when combined with lifestyle modifications.

At Cured Pharmacy, Wegovy is available from £79.00 per pen after applying discount code WEIGHTLOSSNEW during checkout — a reduction from the standard £79.00 price. This transparent pricing includes your UK prescriber consultation, prescription review, and discreet delivery to your door. Treatment requires a clinical assessment by our UK-registered prescribers, completed online in under three minutes, with no hidden fees or subscription lock-ins.

Wegovy follows a dose escalation schedule over 16-20 weeks, starting at 0.25mg weekly and gradually increasing to the maintenance dose of 2.4mg weekly [2]. This gradual titration helps minimise gastrointestinal side effects whilst your body adjusts to the medication. Your prescriber will determine the appropriate dosing schedule based on your individual response and tolerance.

Clinical Evidence: STEP Trial Results for Semaglutide

The STEP clinical trial programme provides robust evidence for Wegovy's efficacy in weight management. In the landmark STEP 1 trial, participants taking semaglutide 2.4mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% in the placebo group [1]. Nearly one-third of participants lost 20% or more of their initial body weight, representing clinically significant improvements in metabolic health markers.

STEP 2 specifically examined semaglutide in patients with type 2 diabetes, demonstrating an average weight loss of 9.6% alongside improved glycaemic control [3]. The STEP 3 trial combined semaglutide with intensive behavioural therapy, achieving average reductions of 16.0% — the highest across the programme [3]. These results established semaglutide as one of the most effective pharmacological interventions for obesity currently available in the UK.

Long-term data from STEP 4 showed that patients who discontinued semaglutide regained approximately two-thirds of their lost weight within one year, whilst those continuing treatment maintained their weight reduction [4]. This underscores the importance of viewing Wegovy as a long-term treatment rather than a short-term intervention, subject to ongoing prescriber review and clinical appropriateness.

Real-World Effectiveness Beyond Clinical Trials

Whilst clinical trials provide controlled evidence, real-world data from UK prescribing patterns shows similar effectiveness when patients adhere to treatment protocols and lifestyle modifications. Your Cured Pharmacy prescriber will discuss realistic expectations during your consultation, as individual results vary based on starting weight, adherence, dietary changes, and physical activity levels. Most patients begin noticing appetite suppression within the first 2-4 weeks of treatment, with measurable weight loss typically evident by week 8-12.

Wegovy vs Alternative Weight Loss Treatments

Several prescription weight loss medications are licensed in the UK, each with distinct mechanisms, efficacy profiles, and administration methods. Wegovy (semaglutide) is a GLP-1 receptor agonist administered via once-weekly subcutaneous injection, offering convenience compared to daily injection alternatives. The once-weekly dosing schedule improves treatment adherence and fits more easily into patients' routines.

Saxenda (liraglutide) is an earlier GLP-1 medication requiring daily injections, whilst Orlistat works through a different mechanism by blocking fat absorption in the digestive system rather than affecting appetite hormones. Mysimba combines naltrexone and bupropion to target reward pathways and appetite centres in the brain. Each treatment has specific eligibility criteria, contraindications, and side effect profiles that your UK prescriber will evaluate during your clinical assessment.

Head-to-head trials comparing semaglutide to liraglutide showed significantly greater weight loss with semaglutide — an average difference of approximately 5-6 percentage points in total body weight reduction [5]. However, treatment selection depends on individual patient factors including medical history, previous treatment responses, injection frequency preference, and cost considerations. No single treatment is universally superior; the right choice varies by patient circumstances.

How to Use Your Wegovy Discount Code at Cured Pharmacy

Accessing your discounted Wegovy UK cost is straightforward at Cured Pharmacy. Begin by clicking 'Start Assessment' on the Wegovy product page, which initiates your free online consultation with our UK-registered clinical team. The consultation takes under three minutes and covers your medical history, current medications, weight loss goals, and any contraindications to semaglutide therapy.

Once your prescriber approves your treatment — subject to clinical appropriateness — you'll proceed to checkout where you can apply discount code WEIGHTLOSSNEW to reduce your price to £79.00 per pen. The code applies automatically to eligible orders, with no minimum purchase requirements or subscription commitments. Your order is then dispensed by our GPhC-registered pharmacy (registration number 9012511) under the supervision of superintendent pharmacist Tarun Kumar (GPhC 2233073).

Delivery is discreet and typically arrives within 2-4 working days via tracked courier. Each Wegovy pen arrives with full patient information leaflets, injection instructions, and access to our pharmacy team for any questions about administration technique or side effect management. Repeat prescriptions can be ordered through your online account, with your prescriber reviewing ongoing suitability at regular intervals as required by UK prescribing regulations.

Prescription Requirements and Clinical Assessment

Wegovy is a prescription-only medicine (POM) in the UK and cannot legally be supplied without a valid prescription from a UK-registered prescriber. Our clinical team assesses eligibility based on MHRA-approved criteria: BMI ≥30 kg/m², or BMI ≥27 kg/m² with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidaemia. Certain medical conditions and medications may contraindicate semaglutide use, which your prescriber will evaluate during your consultation. If Wegovy is not clinically appropriate, alternative treatments may be recommended.

Managing Side Effects and Treatment Expectations

The most commonly reported side effects of Wegovy are gastrointestinal, including nausea, diarrhoea, vomiting, constipation, and abdominal discomfort [2]. These effects are typically mild to moderate, most pronounced during dose escalation phases, and tend to diminish as treatment continues. The gradual dose titration schedule is specifically designed to minimise these symptoms whilst allowing your body to adapt to the medication.

Practical strategies to reduce gastrointestinal side effects include eating smaller, more frequent meals, avoiding high-fat foods, staying well-hydrated, and taking the injection on the same day each week. If nausea persists, your prescriber may recommend temporarily maintaining your current dose for an additional week before increasing, or prescribing anti-nausea medication for short-term symptom relief. Severe or persistent side effects should always be discussed with your prescriber or GP.

Rare but serious side effects include pancreatitis, gallbladder problems, and hypoglycaemia (particularly in patients taking diabetes medications). Wegovy carries a black box warning in some jurisdictions regarding thyroid C-cell tumours observed in rodent studies, though human relevance remains uncertain [6]. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not use Wegovy. Your clinical assessment will screen for these contraindications before prescribing.

Long-Term Weight Management and Treatment Duration

Wegovy is intended as a long-term treatment for chronic weight management, not a short-term fix. NICE guidance recommends continuing treatment only if patients achieve at least 5% weight loss after 6 months at the maintenance dose, demonstrating clinical benefit [7]. Your prescriber will monitor your progress at regular intervals, typically every 3-6 months, to assess ongoing effectiveness and appropriateness of continued treatment.

Weight loss typically plateaus after 12-18 months of treatment, at which point the focus shifts to weight maintenance and preventing regain. Lifestyle modifications — including dietary changes, increased physical activity, and behavioural strategies — remain essential components of successful long-term outcomes. Wegovy enhances these efforts by reducing appetite and increasing satiety, but cannot replace fundamental lifestyle changes.

If you discontinue Wegovy, gradual weight regain is common, as demonstrated in STEP 4 trial data [4]. Some patients may require ongoing treatment indefinitely to maintain weight loss, whilst others successfully transition to lifestyle-only maintenance after achieving their goals. Your prescriber will develop an individualised plan based on your response, weight loss targets, metabolic improvements, and personal preferences. Treatment costs should be considered as part of long-term budgeting for chronic disease management.

Combining Wegovy With Lifestyle Modifications

Clinical trials demonstrating Wegovy's efficacy all included lifestyle intervention components alongside medication. Optimal results occur when semaglutide is combined with a reduced-calorie diet (typically 500-1000 kcal/day deficit) and at least 150 minutes of moderate-intensity physical activity weekly. Your prescriber may recommend referral to dietetic services, weight management programmes, or exercise specialists to support comprehensive behaviour change. Medication alone, whilst effective, produces better outcomes when integrated into a holistic treatment approach addressing the multiple factors contributing to obesity.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Electronic Medicines Compendium. Retrieved from https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
3. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
4. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
5. O'Neil, P. M., Birkenfeld, A. L., McGowan, B., et al. (2018). Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet, 392(10148), 637–649. https://doi.org/10.1016/S0140-6736(18)31773-2 [accessed 13 August 2026]
6. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy (semaglutide): Risk of thyroid C-cell tumours. Drug Safety Update. Retrieved from https://www.gov.uk/drug-safety-update [accessed 13 August 2026]
7. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity: Technology appraisal guidance [TA875]. Retrieved from https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary. Wegovy is indicated for chronic weight management in adults with a BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities, alongside dietary and exercise modifications.